Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688513'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.27 Med: 9.61 Max: 20.29
Current: 8.03
During the past 13 years, Chengdu Easton Biopharmaceuticals Co's highest Return-on-Tangible-Asset was 20.29%. The lowest was 7.27%. And the median was 9.61%.
SHSE:688513's Return-on-Tangible-Asset is ranked better than 89.89% of 1415
companies
in the Biotechnology industry
Industry Median: -35.77
vs SHSE:688513: 8.03
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Asset Related Terms
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Asset Chart
SHSE:688513 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.07% mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Return-on-Tangible-Asset of 9.07% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is near median its historical median of 9.61. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset has ranged from 7.27 to 20.29. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #143 out of 1415 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset too high?
Chengdu Easton Biopharmaceuticals Co's current Return-on-Tangible-Asset of 9.07% is near median its 10-year median of 9.61. Over the past 10 years, this metric has ranged from a low of 7.27 to a high of 20.29. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #143 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #143 out of 1415 companies for Return-on-Tangible-Asset. This places Chengdu Easton Biopharmaceuticals Co in the top 10% of its industry — outperforming the majority of peers. Historically, Chengdu Easton Biopharmaceuticals Co's own Return-on-Tangible-Asset has ranged from 7.27 to 20.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Return-on-Tangible-Asset is 9.07%, which is near median its own 10-year median of 9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥46.44, compared to a current price of ¥45.56 — trading 1.9% below its estimated fair value. The current Return-on-Tangible-Asset is 9.07%, which is near median its 10-year median of 9.61. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Return-on-Tangible-Asset is 9.07% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥45.56 is trading 1.9% below its estimated GF Value™ of ¥46.44.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
Return-on-Tangible-Asset: 9.07% (near median its 10-year median of 9.61)
GF Value™: ¥46.44 vs. price of ¥45.56 (1.9% below fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
97GF Score
Get the complete analysis for SHSE:688513
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
